Abstract: This application discloses an audio processing method and a terminal. The method may include: collecting, by a first terminal, an original speech of a first user, translating the original speech of the first user into a translated speech of the first user, receiving an original speech of a second user that is sent by a second terminal, and translating the original speech of the second user into a translated speech of the second user; sending at least one of the original speech of the first user, the translated speech of the first user, and the translated speech of the second user to the second terminal based on a first setting; and playing at least one of the original speech of the second user, the translated speech of the second user, and the translated speech of the first user based on a second setting.

Abstract: The present invention provides a novel vaccine for preventing and treating Merkel cell carcinoma. The present invention constructs a therapeutic vaccine based on a Merkel cell polyomavirus capsid protein VP1 by taking the Merkel cell polyomavirus capsid protein VP1 as an antigen, in combination with a TLR agonist. The present invention effectively solves the problem of prevention and treatment of the Merkel cell carcinoma and has great application value and application prospects.

Abstract: An immune enhancer comprising at least an interferon and a granulocyte-macrophage colony-stimulating factor, and an immunotherapeutic phar-maceutical composition comprising at least an antigen and the above-mentioned immune enhancers is disclosed. A preparation method of the immunotherapeutic pharmaceutical composition, the use of the immune enhancer and the immunotherapeutic pharmaceutical composition are also disclosed. The immune enhancer can be applied to disease and tumor treatments caused by viruses, bacteria, and other microorganisms.

Abstract: Immune compositions comprising (i) a respiratory syncytial virus (RSV) G polypeptide, which may be a modified G polypeptide relative to the wild-type counterpart, or a nucleic acid encoding such, and (ii) a solvent and one or more immune regulators, wherein the immune regulator(s) is dissolvable in the solvent. Also provided herein are methods for eliciting anti-RSV immune responses using the immune compositions disclosed herein and methods for producing the immune compositions.

Abstract: The present invention provides an immune enhancer comprising at least an interferon and a granulocyte-macrophage colony-stimulating factor, and an immunotherapeutic pharmaceutical composition comprising at least an antigen and the above-mentioned immune enhancers. The present invention further discloses a preparation method of the immunotherapeutic pharmaceutical composition, the use of the immune enhancer and the immunotherapeutic pharmaceutical composition. The immune enhancer can be applied to disease and tumor treatments caused by viruses, bacteria, and other microorganisms.

Abstract: This application discloses an audio processing method and a terminal. The method may include: collecting, by a first terminal, an original speech of a first user, translating the original speech of the first user into a translated speech of the first user, receiving an original speech of a second user that is sent by a second terminal, and translating the original speech of the second user into a translated speech of the second user; sending at least one of the original speech of the first user, the translated speech of the first user, and the translated speech of the second user to the second terminal based on a first setting; and playing at least one of the original speech of the second user, the translated speech of the second user, and the translated speech of the first user based on a second setting.

Abstract: Immune compositions comprising (i) a respiratory syncytial virus (RSV) G polypeptide, which may be a modified G polypeptide relative to the wild-type counterpart, or a nucleic acid encoding such, and (ii) a solvent and one or more immune regulators, wherein the immune regulator(s) is dissolvable in the solvent. Also provided herein are methods for eliciting anti-RSV immune responses using the immune compositions disclosed herein and methods for producing the immune compositions.

Abstract: A laminating roller assembly comprises a frame, a movable support supported by the frame, a laminating roller and a lift mechanism. The laminating roller is attached to the movable support. The lift mechanism is attached to the frame and is configured to move the movable support and the attached laminating roller relative to the frame. Additional embodiments of the invention are directed to a credential substrate laminator and a method of laminating a credential substrate using a credential substrate laminator.

Abstract: A laminating roller assembly comprises a frame, a movable support supported by the frame, a laminating roller and a lift mechanism. The laminating roller is attached to the movable support. The lift mechanism is attached to the frame and is configured to move the movable support and the attached laminating roller relative to the frame. Additional embodiments of the invention are directed to a credential substrate laminator and a method of laminating a credential substrate using a credential substrate laminator.

Abstract: A feature in a layer is provided. A photoresist layer is formed over the layer. The photoresist layer is patterned to form photoresist features with photoresist sidewalls, where the photoresist features have a first critical dimension. A conformal layer is deposited over the sidewalls of the photoresist features to reduce the critical dimensions of the photoresist features. Features are etched into the layer, wherein the layer features have a second critical dimension, which is less than the first critical dimension.

Abstract: A feature in a layer is provided. A photoresist layer is formed over the layer. The photoresist layer is patterned to form photoresist features with photoresist sidewalls, where the photoresist features have a first critical dimension. A conformal layer is deposited over the sidewalls of the photoresist features to reduce the critical dimensions of the photoresist features. Features are etched into the layer, wherein the layer features have a second critical dimension, which is less than the first critical dimension.